← Leaderboards
Andrew Zhuang Wang
Univ Of North Carolina Chapel Hill
$7,157,631
Attributed
$8,235,779
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,235,779 · 7
By mechanism
R01$6,017,768 · 4
U54$1,274,372 · 1
R21$643,639 · 1
R56$300,000 · 1
Top collaborators
- Jianjun Cheng3 shared
- Cecilia Maria Leal1 shared
- Olaf Stuve1 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Leon Garland Coleman$2,583,780
- Jonathan Stuart Serody$17,391,591
- Ilona Jaspers$20,767,326
- Teresa Kathleen Tarrant$745,145
- Christin E Burd$5,593,902
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoInnovationEngineeringTumorMalignant NeoplasmsNanoparticleInhibitor/AntagonistNeoplastic CellDisease ModelTranslatingTreatment EfficacyArtificial NanoparticlesSuccessCellsPropertyPreventRadiation TherapyPharmaceutical PreparationsChemistryIn VitroCancer TherapyNanomedicineTissuesLead
Grant awards (25)
Tissue engineered organ-specific cancer metastasis model for cancer research$544,475
R01 · FY2025 · CA · contact PI
Immune Checkpoint-Engineered oligodendrocytes as treatment for multiple sclerosis$300,000
R56 · FY2025 · AI · contact PI
Tissue engineered organ-specific cancer metastasis model for cancer research$544,475
R01 · FY2024 · CA · contact PI
Basement Membrane Targeted Nanoparticles for Post-Surgical Adhesion Prevention$393,605
R01 · FY2022 · GM · contact PI
Targeting through Selective Cell Labeling$443,066
R01 · FY2021 · EB
Basement Membrane Targeted Nanoparticles for Post-Surgical Adhesion Prevention$221,938
R01 · FY2021 · GM · contact PI
Basement Membrane Targeted Nanoparticles for Post-Surgical Adhesion Prevention$159,536
R01 · FY2021 · GM · contact PI
Targeting through Selective Cell Labeling$465,127
R01 · FY2020 · EB
Basement Membrane Targeted Nanoparticles for Post-Surgical Adhesion Prevention$373,205
R01 · FY2020 · GM · contact PI
Targeting through Selective Cell Labeling$469,752
R01 · FY2019 · EB
Basement Membrane Targeted Nanoparticles for Post-Surgical Adhesion Prevention$373,205
R01 · FY2019 · GM · contact PI
Project 3: Combining Radiotherapy and Nanotechnology for Immunotherapy$229,095
U54 · FY2019 · CA · contact PI
Targeting through Selective Cell Labeling$478,351
R01 · FY2018 · EB
Project 3: Combining Radiotherapy and Nanotechnology for Immunotherapy$239,179
U54 · FY2018 · CA · contact PI
Nanoparticle formulations of DNA repair inhibitors to improve chemoradiotherapy$312,079
R01 · FY2017 · CA · contact PI
Project 3: Combining Radiotherapy and Nanotechnology for Immunotherapy$301,276
U54 · FY2017 · CA · contact PI
Nanoparticle formulations of DNA repair inhibitors to improve chemoradiotherapy$312,079
R01 · FY2016 · CA · contact PI
Project 3: Combining Radiotherapy and Nanotechnology for Immunotherapy$265,644
U54 · FY2016 · CA · contact PI
Nanoparticle formulations of DNA repair inhibitors to improve chemoradiotherapy$312,079
R01 · FY2015 · CA · contact PI
Development of 3D organ-specific models of colorectal cancer metastasis$260,571
R21 · FY2015 · CA · contact PI
Project 3: Combining Radiotherapy and Nanotechnology for Immunotherapy$239,178
U54 · FY2015 · CA · contact PI
Nanoparticle formulations of DNA repair inhibitors to improve chemoradiotherapy$302,717
R01 · FY2014 · CA · contact PI
Development of 3D organ-specific models of colorectal cancer metastasis$188,617
R21 · FY2014 · CA · contact PI
Nanoparticle formulations of DNA repair inhibitors to improve chemoradiotherapy$312,079
R01 · FY2013 · CA · contact PI
Development of 3D organ-specific models of colorectal cancer metastasis$194,451
R21 · FY2013 · CA · contact PI